These investments further strengthen Roche’s already significant US footprint, which includes 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions. They are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 jobs at new and expanded facilities.

As part of this investment, Roche will increase its existing footprint of more than 25,000 employees in 24 sites across eight US states. The investment will include: 

• Expanded and upgraded US manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon, and California
• A state-of-the-art gene therapy manufacturing facility in Pennsylvania
• A new 900,000 square foot manufacturing centre to support Roche’s expanding portfolio of next-generation weight loss medicines (location to be announced)
• A new manufacturing facility for continuous glucose monitoring in Indiana
• A new R&D centre in Massachusetts, conducting cutting-edge artificial intelligence (AI) research and serving as a hub for our new cardiovascular, renal, and metabolism research and development efforts
• Significant expansion and upgrading of our existing pharmaceuticals and diagnostics R&D centres in Arizona, Indiana, and California

“Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development, and manufacturing in the US,” said Thomas Schinecker, Roche Group CEO. “We are proud of our 110-year legacy in the United States, which has been a key driver for jobs, innovation, and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”

Once all new and expanded manufacturing capacity comes online, Roche will export more medicines from the US than it imports. Today, its diagnostics division already has an export surplus from the US to other countries.